Volume 11, Number 6—June 2005
Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031
|Macrolide-resistant phenotype||Pulsed-field gel electrophoresis cluster (emm type)||Frequency (n = 506)||No. (%) of macrolide-resistant S. pyogenes
|1999 (n = 81)||2000 (n = 41)||2001 (n = 73)||2002 (n = 215)||2003 (n = 96)|
|Constitutive||1 (emm22)||70||45 (56%)||7 (17%)†||9 (12%)||7 (3%)||2 (2%)|
|4 (emm28)||45||–||–||4 (5%)||15 (7%)||26 (27%)|
|23 (emm11)||28||–||–||1 (1%)||6 (3%)||21 (22%)|
|M||1001 (emm1)||128||7 (9%)||12 (29%)||23 (32%)||80 (37%)‡||6 (6%)‡|
|1002 (emm4 )||28||2 (2.5%)||2 (5%)||7 (10%)||7 (3%)||10 (10%)|
*A ≤6-band difference was employed to assign isolates to a clone according to Tenover et al. (8). PFGE clusters up to 100 designate restriction with SmaI and clusters ≥1,000 designate restriction with SfiI.
†Decrease in prevalence of the 1/emm22 clone from 1999 to 2000 was highly significant (p<0.001).
‡Both the increase and decrease in prevalence of the 1001/emm1 clone from 2001 to 2002 and from 2002 to 2003, respectively, were significant (p<0.01).
- Descheemaeker P, Chapelle S, Lammens C, Hauchecorne M, Wijdooghe M, Vandamme P, Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother. 2000;45:167–73. DOIPubMedGoogle Scholar
- Canton R, Loza E, Morosini MI, Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROTEKT antimicrobial surveillance programme during 1999–2000. J Antimicrob Chemother. 2002;50(Suppl S1):9–24. DOIPubMedGoogle Scholar
- Cornaglia G, Ligozzi M, Mazzariol A, Masala L, Lo CG, Orefici G, Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance. Clin Infect Dis. 1998;27(Suppl 1):S87–92. DOIPubMedGoogle Scholar
- Szczypa K, Sadowy E, Izdebski R, Hryniewicz W. A rapid increase in macrolide resistance in Streptococcus pyogenes isolated in Poland during 1996–2002. J Antimicrob Chemother. 2004;54:828–31. DOIPubMedGoogle Scholar
- Iannelli F, Santagati M, Docquier JD, Cassone M, Oggioni MR, Rossolini G, Type M resistance to macrolides in streptococci is not due to the mef(A) gene, but to mat(A) encoding an ATP-dependent efflux pump [Abstract C1-1188]. Presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington; 2004 Oct 30–Nov 2.
- Reinert RR, Lutticken R, Sutcliffe JA, Tait-Kamradt A, Cil MY, Schorn HM, Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany. Antimicrob Agents Chemother. 2004;48:1369–73. DOIPubMedGoogle Scholar
- NCCLS. National Committee for Clinical laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement, M100-S12. Wayne (PA); The Committee; 2002.
- Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33:2233–9.PubMedGoogle Scholar
- Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother. 1996;40:2562–6.PubMedGoogle Scholar
- Malhotra-Kumar S, Wang S, Lammens C, Chapelle S, Goossens H. Bacitracin-resistant clone of Streptococcus pyogenes isolated from pharyngitis patients in Belgium. J Clin Microbiol. 2003;41:5282–4. DOIPubMedGoogle Scholar
- Malbruny B, Nagai K, Coquemont M, Bozdogan B, Andrasevic AT, Hupkova H, Resistance to macrolides in clinical isolates of Streptococcus pyogenes due to ribosomal mutations. J Antimicrob Chemother. 2002;49:935–9. DOIPubMedGoogle Scholar
- Novotny GW, Jakobsen L, Andersen NM, Poehlsgaard J, Douthwaite S. Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA. Antimicrob Agents Chemother. 2004;48:3677–83. DOIPubMedGoogle Scholar
- Garcia-Rey C, Aguilar L, Baquero F, Casal J, Martin JE. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol. 2002;40:2959–63. DOIPubMedGoogle Scholar
- Bergman M, Huikko S, Pihlajamaki M, Laippala P, Palva E, Huovinen P, Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997–2001. Clin Infect Dis. 2004;38:1251–6. DOIPubMedGoogle Scholar
- Granizo JJ, Aguilar L, Casal J, Dal Re R, Baquero F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986–1997). J Antimicrob Chemother. 2000;46:959–64. DOIPubMedGoogle Scholar
- Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance. Lancet. 2005;365:579–87.PubMedGoogle Scholar
- Weber P, Filipecki J, Bingen E, Fitoussi F, Goldfarb G, Chauvin JP, Genetic and phenotypic characterization of macrolide resistance in group A streptococci isolated from adults with pharyngo-tonsillitis in France. J Antimicrob Chemother. 2001;48:291–4. DOIPubMedGoogle Scholar
- Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis. Lancet. 2001;358:1334–7. DOIPubMedGoogle Scholar
- Nielsen HU, Hammerum AM, Ekelund K, Bang D, Pallesen LV, Frimodt-Moller N. Tetracycline and macrolide co-resistance in Streptococcus pyogenes: co-selection as a reason for increase in macrolide-resistant S. pyogenes? Microb Drug Resist. 2004;10:231–8.PubMedGoogle Scholar
1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.